These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
251 related items for PubMed ID: 18854869
1. How to tackle the diagnosis of limb-girdle muscular dystrophy 2A. Fanin M, Nascimbeni AC, Tasca E, Angelini C. Eur J Hum Genet; 2009 May; 17(5):598-603. PubMed ID: 18854869 [Abstract] [Full Text] [Related]
2. Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations. Fanin M, Nascimbeni AC, Angelini C. J Med Genet; 2007 Jan; 44(1):38-43. PubMed ID: 16971480 [Abstract] [Full Text] [Related]
3. Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Fanin M, Fulizio L, Nascimbeni AC, Spinazzi M, Piluso G, Ventriglia VM, Ruzza G, Siciliano G, Trevisan CP, Politano L, Nigro V, Angelini C. Hum Mutat; 2004 Jul; 24(1):52-62. PubMed ID: 15221789 [Abstract] [Full Text] [Related]
7. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Fanin M, Nascimbeni AC, Aurino S, Tasca E, Pegoraro E, Nigro V, Angelini C. Neurology; 2009 Apr 21; 72(16):1432-5. PubMed ID: 19380703 [Abstract] [Full Text] [Related]
8. cDNA analyses of CAPN3 enhance mutation detection and reveal a low prevalence of LGMD2A patients in Denmark. Duno M, Sveen ML, Schwartz M, Vissing J. Eur J Hum Genet; 2008 Aug 21; 16(8):935-40. PubMed ID: 18337726 [Abstract] [Full Text] [Related]
13. Diagnosis of limb-girdle muscular dystrophy 2A by immunohistochemical techniques. Kolski HK, Hawkins C, Zatz M, de Paula F, Biggar D, Alman B, Vajsar J. Neuropathology; 2008 Jun 21; 28(3):264-8. PubMed ID: 18031465 [Abstract] [Full Text] [Related]
14. Epidemiological and Molecular Characterization of a Mexican Population Isolate with High Prevalence of Limb-Girdle Muscular Dystrophy Type 2A Due to a Novel Calpain-3 Mutation. Pantoja-Melendez CA, Miranda-Duarte A, Roque-Ramirez B, Zenteno JC. PLoS One; 2017 Jun 21; 12(1):e0170280. PubMed ID: 28103310 [Abstract] [Full Text] [Related]
17. Immunohistochemical analysis of calpain 3: advantages and limitations in diagnosing LGMD2A. Charlton R, Henderson M, Richards J, Hudson J, Straub V, Bushby K, Barresi R. Neuromuscul Disord; 2009 Jul 21; 19(7):449-57. PubMed ID: 19556129 [Abstract] [Full Text] [Related]
18. A single c.1715G>C calpain 3 gene variant causes dominant calpainopathy with loss of calpain 3 expression and activity. Vissing J, Dahlqvist JR, Roudaut C, Poupiot J, Richard I, Duno M, Krag T. Hum Mutat; 2020 Sep 21; 41(9):1507-1513. PubMed ID: 32557990 [Abstract] [Full Text] [Related]